. 2016 Dec;389(10087).
doi: 10.1016/S0140-6736(16)32419-9.

Advances in the treatment of advanced oestrogen-receptor-positive breast cancer

Nicholas C Turner 1 Patrick Neven 2 Sibylle Loibl 3 Fabrice Andre 4 
  • PMID: 27939057
  •     42 citations


Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development of resistance to therapy is inevitable in advanced cancer. Major progress has been made in identifying the drivers of oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy. This progress has translated into major advances in the treatment of advanced breast cancer, with several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially improve progression-free survival. A new wave of targeted therapies is being developed, including inhibitors of PI3K, AKT, and HER2, and a new generation of oestrogen-receptor degraders. Considerable challenges remain in patient selection, deciding on the most appropriate order in which to administer therapies, and establishing whether cross-resistance occurs between therapies.

G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer.
Christina Y Yim, Emmanuel Bikorimana, +6 authors, Michael J Spinella.
Cell cycle (Georgetown, Tex.), 2017 Sep 15; 16(21). PMID: 28910567    Free PMC article.
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
J H Chung, D Pavlick, +23 authors, S M Ali.
Ann Oncol, 2017 Sep 26; 28(11). PMID: 28945887    Free PMC article.
A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer.
Yannan Zhao, Chengcheng Gong, +8 authors, Xichun Hu.
Oncotarget, 2017 Nov 16; 8(48). PMID: 29137418    Free PMC article.
Roles of estrogens on myeloid-derived suppressor cells in cancer and autoimmune diseases.
Jing Ren, Yayi Hou, Tingting Wang.
Cell Mol Immunol, 2017 Dec 26; 15(7). PMID: 29276217    Free PMC article.
Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model.
Zhenchong Xiong, Guangzheng Deng, +5 authors, Xi Wang.
Cancer Res Treat, 2018 Jan 16; 50(4). PMID: 29334609    Free PMC article.
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.
Sri Lakshmi Hyndavi Yeruva, Fengmin Zhao, +5 authors, Roisin M Connolly.
NPJ Breast Cancer, 2018 Jan 23; 4. PMID: 29354686    Free PMC article.
Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
Francesca Poggio, Matteo Lambertini, Evandro de Azambuja.
ESMO Open, 2018 Feb 02; 3(1). PMID: 29387483    Free PMC article.
Melatonin: A Molecule for Reducing Breast Cancer Risk.
Alicia González-González, María Dolores Mediavilla, Emilio J Sánchez-Barceló.
Molecules, 2018 Feb 09; 23(2). PMID: 29415446    Free PMC article.
Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence.
Eileen M McGowan, Yiguang Lin, Diana Hatoum.
Cancers (Basel), 2018 Jun 03; 10(6). PMID: 29857525    Free PMC article.
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Stephen J Luen, Rebecca Asher, +13 authors, Sherene Loi.
JAMA Oncol, 2018 Jun 15; 4(10). PMID: 29902286    Free PMC article.
Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade.
Brijesh Kumar, Mayuri Prasad, +9 authors, Harikrishna Nakshatri.
Cancer Res, 2018 Jul 13; 78(17). PMID: 29997232    Free PMC article.
Outcomes and prognostic factors for surgically treated patients with breast cancer spine metastases.
Chenglong Zhao, Zhichao Zhang, +6 authors, Jianru Xiao.
J Bone Oncol, 2018 Jul 28; 12. PMID: 30050751    Free PMC article.
microRNA Let-7b: A Novel treatment for endometriosis.
Cagdas Sahin, Ramanaiah Mamillapalli, Kyong W Yi, Hugh S Taylor.
J Cell Mol Med, 2018 Aug 01; 22(11). PMID: 30063121    Free PMC article.
Updates on managing advanced breast cancer with palbociclib combination therapy.
Teresa M McShane, Thomas A Wolfe, Joanne C Ryan.
Ther Adv Med Oncol, 2018 Sep 12; 10. PMID: 30202448    Free PMC article.
Subcellular Targeting of Theranostic Radionuclides.
Bas M Bavelaar, Boon Q Lee, +2 authors, Katherine A Vallis.
Front Pharmacol, 2018 Sep 21; 9. PMID: 30233374    Free PMC article.
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.
Yannan Zhao, Cheng Liu, +6 authors, Biyun Wang.
Sci Rep, 2018 Sep 29; 8(1). PMID: 30262849    Free PMC article.
AFF3 upregulation mediates tamoxifen resistance in breast cancers.
Yawei Shi, Yang Zhao, +5 authors, Shenming Wang.
J Exp Clin Cancer Res, 2018 Oct 18; 37(1). PMID: 30326937    Free PMC article.
The fluctuating incidence, improved survival of patients with breast cancer, and disparities by age, race, and socioeconomic status by decade, 1981-2010.
Guanming Lu, Jie Li, +6 authors, Haiqing Ma.
Cancer Manag Res, 2018 Nov 23; 10. PMID: 30464592    Free PMC article.
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Suryavathi Viswanadhapalli, Shihong Ma, +17 authors, Ratna K Vadlamudi.
Breast Cancer Res, 2019 Dec 28; 21(1). PMID: 31878959    Free PMC article.
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer.
Scott F Schoninger, Stacy W Blain.
Molecular cancer therapeutics, 2020 Jan 08; 19(1). PMID: 31909732    Free PMC article.
Cystatin SN Affects Cell Proliferation by Regulating the ERα/PI3K/AKT/ERα Loopback Pathway in Breast Cancer.
Yanfang Liu, Hong Ma, +2 authors, Jing Yao.
Onco Targets Ther, 2020 Jan 11; 12. PMID: 31920327    Free PMC article.
ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway.
Guangliang Li, Jing Zhang, Zhenzhen Xu, Zhongqi Li.
Cancer Manag Res, 2020 Feb 06; 12. PMID: 32021441    Free PMC article.
Association between socioeconomic factors at diagnosis and survival in breast cancer: A population-based study.
Peng Ji, Yue Gong, +3 authors, Zhi-Ming Shao.
Cancer Med, 2020 Jan 22; 9(5). PMID: 31960597    Free PMC article.
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
Ben O'Leary, Rosalind J Cutts, +10 authors, Nicholas C Turner.
Cancer Discov, 2018 Sep 13; 8(11). PMID: 30206110    Free PMC article.
Highly Cited.
The LIM protein Ajuba recruits DBC1 and CBP/p300 to acetylate ERα and enhances ERα target gene expression in breast cancer cells.
Beihui Xu, Qi Li, +8 authors, Zhaoyuan Hou.
Nucleic Acids Res, 2019 Jan 01; 47(5). PMID: 30597111    Free PMC article.
Editorial Comment: 2017 Musculoskeletal Tumor Society Proceedings.
John H Healey.
Clin Orthop Relat Res, 2019 Feb 28; 477(4). PMID: 30811356    Free PMC article.
MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer.
Chen Khuan Wong, Christopher Gromisch, +5 authors, Sam Thiagalingam.
Cancer biology & therapy, 2019 Mar 30; 20(8). PMID: 30922194    Free PMC article.
ERα, A Key Target for Cancer Therapy: A Review.
Yanfang Liu, Hong Ma, Jing Yao.
Onco Targets Ther, 2020 Mar 27; 13. PMID: 32210584    Free PMC article.
Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at a Single Institution.
Ying-Xue Li, Shan-Shan Ding, +3 authors, Huai-Yin Shi.
Cancer Manag Res, 2020 Mar 27; 12. PMID: 32210617    Free PMC article.
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Noah Kornblum, Fengmin Zhao, +16 authors, Joseph A Sparano.
J Clin Oncol, 2018 Apr 18; 36(16). PMID: 29664714    Free PMC article.
Highly Cited.
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Lacey M Litchfield, Karsten Boehnke, +13 authors, Sean G Buchanan.
Oncotarget, 2020 May 12; 11(17). PMID: 32391118    Free PMC article.
Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer.
Hao Liao, Huiping Li.
Cancer Manag Res, 2020 Jun 18; 12. PMID: 32547192    Free PMC article.
Teaching cross-cultural design thinking for healthcare.
Mafalda Falcão Ferreira, Julia N Savoy, Mia K Markey.
Breast, 2020 Jan 21; 50. PMID: 31958660    Free PMC article.
Iron(II) phthalocyanine Loaded and AS1411 Aptamer Targeting Nanoparticles: A Nanocomplex for Dual Modal Imaging and Photothermal Therapy of Breast Cancer.
Yubei He, Mengzhu Wang, +7 authors, Gengbiao Yuan.
Int J Nanomedicine, 2020 Aug 28; 15. PMID: 32848397    Free PMC article.
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
Elodie Montaudon, Joanna Nikitorowicz-Buniak, +35 authors, Elisabetta Marangoni.
Nat Commun, 2020 Aug 15; 11(1). PMID: 32792481    Free PMC article.
Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.
Mariana Brandão, Christian Maurer, +7 authors, Matteo Lambertini.
ESMO Open, 2020 Aug 28; 5(4). PMID: 32847835    Free PMC article.
Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer.
Danni Chen, Chang Bao, +4 authors, Senxiang Yan.
Front Oncol, 2020 Sep 26; 10. PMID: 32974144    Free PMC article.
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Chrysiis Michaloglou, Claire Crafter, +11 authors, Sabina C Cosulich.
Molecular cancer therapeutics, 2018 Feb 28; 17(5). PMID: 29483206    Free PMC article.
Highly Cited.
Tamoxifen withdrawal in women with progressive metastatic breast cancer: a case series of six patients.
Kanako Hagio, Motoi Baba, +4 authors, Hiroko Yamashita.
Int Cancer Conf J, 2019 Jun 01; 7(4). PMID: 31149534    Free PMC article.
Estrogen Induces Selective Transcription of Caveolin1 Variants in Human Breast Cancer through Estrogen Responsive Element-Dependent Mechanisms.
Antonella Romano, Antonia Feola, +6 authors, Candida Zuchegna.
Int J Mol Sci, 2020 Aug 23; 21(17). PMID: 32825330    Free PMC article.
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Richard S Finn, Massimo Cristofanilli, +11 authors, Hope S Rugo.
Breast Cancer Res Treat, 2020 Aug 13; 184(1). PMID: 32783178    Free PMC article.
Systemic Regulation of Cancer Development by Neuro-Endocrine-Immune Signaling Network at Multiple Levels.
Shu-Heng Jiang, Xiao-Xin Zhang, +6 authors, Zhi-Gang Zhang.
Front Cell Dev Biol, 2020 Oct 30; 8. PMID: 33117814    Free PMC article.